bITH, a blood-based metric of intratumor heterogeneity, is associated with clinical response to immune checkpoint blockade in non-small cell lung cancer

BACKGROUND: Intratumor heterogeneity (ITH) has been associated with poor prognosis in advanced non-small cell cancer (NSCLC) patients receiving immune checkpoint blockade (ICB) therapies. However, there is currently no evidence supporting an ITH metric as a predictor of clinical benefit from ICB. Th...

Descripción completa

Detalles Bibliográficos
Autores principales: Fan, Yun, Liu, Yang, Wang, Liuchun, Cai, Yiran, Cao, Wen, Sun, Wenjie, Zou, Xiao, Li, Bing, Zhang, Zhou, Cai, Shangli, Chuai, Shannon, Han, Yusheng, Pan, Xiaojie, Huang, Dingzhi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2023
Materias:
Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10149223/
https://www.ncbi.nlm.nih.gov/pubmed/37094467
http://dx.doi.org/10.1016/j.ebiom.2023.104564

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10149223/
https://www.ncbi.nlm.nih.gov/pubmed/37094467
http://dx.doi.org/10.1016/j.ebiom.2023.104564

Ejemplares similares